Efineptakin alfa

DB16395InvestigationalProtein Based Therapies

Efineptakin alfa (also known as NT-I7) is a long-acting human interleukin-7 (IL-7) fusion protein that promotes T-cell development, contributing to the immune response. Compared to endogenous IL-7, NT-I7 is more... Compared to endogenous IL-7, NT-I7 is more stable and potent, has a longer half-life, and has better bioavailability.

Mechanism: Pharmacologically active on Interleukin-7 receptor subunit alpha
Curator reviewed
Also known as: Hyleukin · Recombinant human IL-7-HYFC · recombinant human interleukin-7 · Recombinant human interleukin-7 fused to a hybrid crystallizable fragment region of a human antibody (Rhil-7-Hyfc)
Code names: GX-I7 · NT-I7 · TJ-107

Resolves to

Compound

UNII3K3WC6MT6PCAS2026634-47-7

Targets

P16871IL7R

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

40Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Efineptakin alfa, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account